Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 January 2020Website:
http://www.arcutis.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
ARQT Latest News
After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% quarter-over-quarter revenue growth. The growth trend seems poised to continue, with an expanding total patient opportunity and the industry trending away from topical steroids, which present lower efficacy and higher risk.
The consensus price target hints at a 70.3% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Serge Belanger - Needham & Co. Kambiz Yazdi - Jefferies Operator Good day, and welcome to the Arcutis Biotherapeutics 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1 Second approval of ZORYVE outside of the United States, expanding ZORYVE portfolio availability to over 2 million Canadians living with seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older.
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe and well tolerated across all subgroups Data presented at the 2024 European Academy of Dermatology & Venereology Congress WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology and immunology, today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials showing that ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of AD in individuals regardless of race, ethnicity, and Fitzpatrick skin types.
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp Supplemental New Drug Application (sNDA) supported by positive efficacy and safety data from Phase 2b and pivotal Phase 3 trials, and long-term ZORYVE cream plaque psoriasis program WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.
Arcutis Biotherapeutics, Inc. is a biotech company based in California that markets two dermatological products, ZORYVE cream and foam, containing roflumilast, a PDE4 inhibitor. Despite initial struggles post-IPO, Arcutis has seen a significant increase in revenues and a narrowing of losses in Q2 2024, with new product approvals and collaborations. Analysts predict strong growth potential for ZORYVE, but competition in the dermatological market poses a challenge for Arcutis to maintain and grow market share.
What type of business is Arcutis Biotherapeutics?
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for dermatological diseases. The company was previously known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Our company is headquartered in Westlake Village, California. The company has a broad portfolio of drugs with significant potential for treating immune-mediated dermatological diseases and conditions. The company's lead product candidate is ARQ-151, a cream with roflumilast for the treatment of plaque psoriasis. The company is also developing ARQ-154, a roflumilast foam formulation for topical use to treat seborrheic dermatitis and scalp psoriasis. ARQ-252, a selective topical Janus kinase type 1 inhibitor for the treatment of chronic hand eczema and vitiligo. ARQ-255, a local formulation of ARQ-252, developed for deeper penetration into the skin to treat focal alopecia.
What sector is Arcutis Biotherapeutics in?
Arcutis Biotherapeutics is in the Healthcare sector
What industry is Arcutis Biotherapeutics in?
Arcutis Biotherapeutics is in the Biotechnology industry
What country is Arcutis Biotherapeutics from?
Arcutis Biotherapeutics is headquartered in United States
When did Arcutis Biotherapeutics go public?
Arcutis Biotherapeutics initial public offering (IPO) was on 31 January 2020
What is Arcutis Biotherapeutics website?
https://www.arcutis.com
Is Arcutis Biotherapeutics in the S&P 500?
No, Arcutis Biotherapeutics is not included in the S&P 500 index
Is Arcutis Biotherapeutics in the NASDAQ 100?
No, Arcutis Biotherapeutics is not included in the NASDAQ 100 index
Is Arcutis Biotherapeutics in the Dow Jones?
No, Arcutis Biotherapeutics is not included in the Dow Jones index
When was Arcutis Biotherapeutics the previous earnings report?
No data
When does Arcutis Biotherapeutics earnings report?
The next expected earnings date for Arcutis Biotherapeutics is 27 February 2025